Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant

George Chen; Megan Herr; Jan Nowak; Christine Ho; Nikolaos Almyroudis; Kristopher Attwood; John Bonnewell; Marissa Walsh; Brahm Segal; Maureen Ross; Philip McCarthy; Theresa Hahn

doi:10.3324/haematol.2022.281719

Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant

George Chen, Megan Herr, Jan Nowak, Christine Ho, Nikolaos Almyroudis, Kristopher Attwood, John Bonnewell, Marissa Walsh, Brahm Segal, Maureen Ross, Philip McCarthy, Theresa Hahn

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	615-620
Number of pages	6
Journal	Haematologica
Volume	108
Issue number	2
DOIs	https://doi.org/10.3324/haematol.2022.281719
State	Published - Feb 2023
Externally published	Yes

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2022.281719

Cite this

@article{dde58c74bc3042aab4ecc912d846e37d,

title = "Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant",

author = "George Chen and Megan Herr and Jan Nowak and Christine Ho and Nikolaos Almyroudis and Kristopher Attwood and John Bonnewell and Marissa Walsh and Brahm Segal and Maureen Ross and Philip McCarthy and Theresa Hahn",

note = "Funding Information: BS receives research funding from NextCure and Apellis and is on the advisory board for NextCure. GLC receives clinical research funding from Actinium, AlloVir, and Takeda. PLM receives consultancy fees / honoraria / research funding from Bluebird Bio, BMS/Celgene/Juno, Fate Therapeutics, Hikma, Janssen, Karyopharm, Magenta Therapeutics, Novartis, Oncopeptides, Partner Therapeutics, Sanofi, Starton Therapeutics, and Takeda. The remaining authors have no conflicts of interest to disclose. Funding Information: BS receives research funding from NextCure and Apellis and is on the advisory board for NextCure. GLC receives clinical research funding from Actinium, AlloVir, and Takeda. PLM receives consultancy fees / honoraria / research funding from Bluebird Bio, BMS/Celgene/Juno, Fate Therapeutics, Hikma, Janssen, Karyopharm, Magenta Therapeutics, Novartis, Oncopeptides, Partner Therapeutics, Sanofi, Starton Therapeutics, and Takeda. The remaining authors have no conflicts of interest to disclose. This work was supported by Roswell Park Comprehensive Cancer Center and National Cancer Institute (NCI) grant P30CA016056. We gratefully acknowledge the patients described in the study and the clinical team providing care to the patients; without their support, this study could not have been completed.",

year = "2023",

month = feb,

doi = "10.3324/haematol.2022.281719",

language = "English (US)",

volume = "108",

pages = "615--620",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "2",

}

TY - JOUR

T1 - Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant

AU - Chen, George

AU - Herr, Megan

AU - Nowak, Jan

AU - Ho, Christine

AU - Almyroudis, Nikolaos

AU - Attwood, Kristopher

AU - Bonnewell, John

AU - Walsh, Marissa

AU - Segal, Brahm

AU - Ross, Maureen

AU - McCarthy, Philip

AU - Hahn, Theresa

N1 - Funding Information: BS receives research funding from NextCure and Apellis and is on the advisory board for NextCure. GLC receives clinical research funding from Actinium, AlloVir, and Takeda. PLM receives consultancy fees / honoraria / research funding from Bluebird Bio, BMS/Celgene/Juno, Fate Therapeutics, Hikma, Janssen, Karyopharm, Magenta Therapeutics, Novartis, Oncopeptides, Partner Therapeutics, Sanofi, Starton Therapeutics, and Takeda. The remaining authors have no conflicts of interest to disclose. Funding Information: BS receives research funding from NextCure and Apellis and is on the advisory board for NextCure. GLC receives clinical research funding from Actinium, AlloVir, and Takeda. PLM receives consultancy fees / honoraria / research funding from Bluebird Bio, BMS/Celgene/Juno, Fate Therapeutics, Hikma, Janssen, Karyopharm, Magenta Therapeutics, Novartis, Oncopeptides, Partner Therapeutics, Sanofi, Starton Therapeutics, and Takeda. The remaining authors have no conflicts of interest to disclose. This work was supported by Roswell Park Comprehensive Cancer Center and National Cancer Institute (NCI) grant P30CA016056. We gratefully acknowledge the patients described in the study and the clinical team providing care to the patients; without their support, this study could not have been completed.

PY - 2023/2

Y1 - 2023/2

UR - http://www.scopus.com/inward/record.url?scp=85147234577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147234577&partnerID=8YFLogxK

U2 - 10.3324/haematol.2022.281719

DO - 10.3324/haematol.2022.281719

M3 - Letter

C2 - 36263844

AN - SCOPUS:85147234577

SN - 0390-6078

VL - 108

SP - 615

EP - 620

JO - Haematologica

JF - Haematologica

IS - 2

ER -

Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this